ZA200805044B - Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination - Google Patents

Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination

Info

Publication number
ZA200805044B
ZA200805044B ZA200805044A ZA200805044A ZA200805044B ZA 200805044 B ZA200805044 B ZA 200805044B ZA 200805044 A ZA200805044 A ZA 200805044A ZA 200805044 A ZA200805044 A ZA 200805044A ZA 200805044 B ZA200805044 B ZA 200805044B
Authority
ZA
South Africa
Prior art keywords
combination
glycoisoforms
septicemia
prevention
treatment
Prior art date
Application number
ZA200805044A
Other languages
English (en)
Inventor
Lopez Ricardo Agustin
Daelli Marcelo Gustavo
Pereira Bacci Dardo Alexis
Amadeo Gabriel Ignacio
Pereiro Miriam Patricia
Christina Noemi Artana
Nestor Maskin
Bernardo Cesar Pistillo
Didier Carolina Etcheve Marina
Kratje Ricardo
Original Assignee
Protech Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protech Pharma S A filed Critical Protech Pharma S A
Publication of ZA200805044B publication Critical patent/ZA200805044B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200805044A 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination ZA200805044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP050104712A AR053416A1 (es) 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac

Publications (1)

Publication Number Publication Date
ZA200805044B true ZA200805044B (en) 2009-08-26

Family

ID=38023621

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805044A ZA200805044B (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination

Country Status (12)

Country Link
US (1) US8343917B2 (es)
EP (1) EP1947115B1 (es)
AR (1) AR053416A1 (es)
AU (1) AU2006313672B2 (es)
BR (1) BRPI0618498A2 (es)
CA (1) CA2629304C (es)
ES (1) ES2396439T3 (es)
IL (1) IL191279A (es)
MA (1) MA30010B1 (es)
MX (1) MX2008006159A (es)
WO (1) WO2007054600A2 (es)
ZA (1) ZA200805044B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
EP1036179B2 (de) 1997-12-03 2014-01-01 Roche Diagnostics GmbH Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US20020169129A1 (en) 1998-02-04 2002-11-14 Zaharia Veronica C. Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO)
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
IL145849A0 (en) * 1999-04-15 2002-07-25 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PL362396A1 (en) 2001-02-06 2004-11-02 Merck Patent Gmbh Modified erythropoietin (epo) with reduced immunogenicity
AU2002335585B2 (en) * 2001-10-29 2007-08-16 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
WO2003046187A1 (en) 2001-11-28 2003-06-05 Sandoz Gmbh Method for producing a recombinant polypeptide
AU2002356749A1 (en) * 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
DE60313125T2 (de) 2002-01-09 2007-12-20 Crucell Holland B.V. Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
US20050153879A1 (en) 2002-03-26 2005-07-14 Monica Svetina Process for the preparation of a desired erythropoietin glyco-isoform profile
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US20040198663A1 (en) 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
WO2004108667A2 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase

Also Published As

Publication number Publication date
WO2007054600B1 (es) 2007-10-18
AU2006313672B2 (en) 2011-12-08
EP1947115B1 (en) 2012-10-17
MX2008006159A (es) 2008-10-09
AR053416A1 (es) 2007-05-09
EP1947115A2 (en) 2008-07-23
EP1947115A4 (en) 2010-03-03
WO2007054600A3 (es) 2007-07-19
BRPI0618498A2 (pt) 2011-09-06
US20090220595A1 (en) 2009-09-03
IL191279A (en) 2012-05-31
WO2007054600A2 (es) 2007-05-18
ES2396439T3 (es) 2013-02-21
AU2006313672A1 (en) 2007-05-18
MA30010B1 (fr) 2008-12-01
US8343917B2 (en) 2013-01-01
CA2629304C (en) 2012-12-04
CA2629304A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
EG25261A (en) Liquid compositions for treating plant propagationmaterials.
EG25251A (en) Synergistic fungicidal compositions.
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
EG25210A (en) Herbicidal compositions.
GB0501579D0 (en) Safety mechanism
EG25034A (en) Stabiliser composition for halide-containing polymers.
EP1764391A4 (en) POLYOL-NETWORKING FLUORESCENT COMPOSITION
GB0503262D0 (en) Antimicrobial composition
EP1957747A4 (en) SAFETY LOCK FOR CONTROL LINES
GB0505634D0 (en) Antimicrobial composition
GB0512667D0 (en) Safety arrangement
GB0511876D0 (en) Bleaching composition
PL1779957T3 (pl) Synergistyczny system spawania
ZA200806311B (en) Primer composition
GB2425313B (en) Fire resisting composition
GB0511874D0 (en) Bleaching composition
ZA200805044B (en) Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination
GB2436054B (en) Biocidal Compositions
GB0505511D0 (en) Attack prevention
GB2429744B (en) Safety barrier
GB0614589D0 (en) Compounds, compositions and processes
GB0622422D0 (en) Contact arrangement for gate or the like
ZA200601604B (en) Composition for treating HIV
HK1144259A1 (en) Medicament for treating or preventing proteinuria